(NUS) Nu Skin Enterprises - Ratings and Ratios
Skin Care, Cosmetics, Nutritional Supplements, Wellness Products, Personal Care
NUS EPS (Earnings per Share)
NUS Revenue
Description: NUS Nu Skin Enterprises
Nu Skin Enterprises Inc is a global developer and distributor of beauty and wellness products, operating through various channels including retail stores, digital platforms, and independent direct sellers. The companys product portfolio includes skin care devices, cosmetics, and nutritional supplements, with popular brands such as ageLOC LumiSpa, LifePak, and Beauty Focus Collagen+.
From a business perspective, Nu Skins diversified product offerings and multi-channel distribution strategy are key strengths. The companys focus on research and product development enables it to stay competitive in the personal care products industry. With a global presence, Nu Skin is well-positioned to capitalize on trends in the beauty and wellness space.
To further analyze Nu Skins performance, key performance indicators (KPIs) such as revenue growth, gross margin, and sales per distributor can be examined. For instance, a steady increase in revenue growth could indicate successful product launches or effective distribution strategies. Additionally, metrics like customer acquisition cost and customer retention rate can provide insights into the companys marketing efficiency and customer loyalty.
From a financial perspective, Nu Skins market capitalization and negative return on equity (RoE) suggest that the company is facing challenges. The absence of P/E ratios may indicate that the company is not generating earnings or is experiencing significant fluctuations in earnings. As a Trading Analyst, it is essential to dig deeper into the companys financials to understand the underlying drivers of its performance and identify potential areas for improvement.
To make informed investment decisions, it is crucial to monitor Nu Skins progress in addressing its challenges and capitalizing on opportunities in the beauty and wellness market. By analyzing KPIs and financial metrics, investors can gain a more comprehensive understanding of the companys prospects and make data-driven decisions.
NUS Stock Overview
| Market Cap in USD | 587m |
| Sub-Industry | Personal Care Products |
| IPO / Inception | 1996-11-21 |
NUS Stock Ratings
| Growth Rating | -24.0% |
| Fundamental | 62.3% |
| Dividend Rating | 14.7% |
| Return 12m vs S&P 500 | 15.9% |
| Analyst Rating | - |
NUS Dividends
| Dividend Yield 12m | 2.50% |
| Yield on Cost 5y | 0.60% |
| Annual Growth 5y | -30.69% |
| Payout Consistency | 96.6% |
| Payout Ratio | 8.3% |
NUS Growth Ratios
| Growth Correlation 3m | 81% |
| Growth Correlation 12m | 54.1% |
| Growth Correlation 5y | -94% |
| CAGR 5y | -21.11% |
| CAGR/Max DD 5y | -0.23 |
| Sharpe Ratio 12m | -1.32 |
| Alpha | 27.01 |
| Beta | 0.648 |
| Volatility | 71.37% |
| Current Volume | 485.1k |
| Average Volume 20d | 623.9k |
| Stop Loss | 11.5 (-5.5%) |
| Signal | 0.00 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (100.8m TTM) > 0 and > 6% of Revenue (6% = 97.6m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA -2.69pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 17.69% (prev 18.76%; Δ -1.07pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 93.4m <= Net Income 100.8m (YES >=105%, WARN >=100%) |
| Net Debt (46.6m) to EBITDA (196.7m) ratio: 0.24 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.01 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (49.5m) change vs 12m ago -0.38% (target <= -2.0% for YES) |
| Gross Margin 67.23% (prev 67.57%; Δ -0.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 107.4% (prev 116.3%; Δ -8.90pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.47 (EBITDA TTM 196.7m / Interest Expense TTM 18.2m) >= 6 (WARN >= 3) |
Altman Z'' 8.81
| (A) 0.20 = (Total Current Assets 571.6m - Total Current Liabilities 283.9m) / Total Assets 1.44b |
| (B) 1.27 = Retained Earnings (Balance) 1.83b / Total Assets 1.44b |
| warn (B) unusual magnitude: 1.27 — check mapping/units |
| (C) 0.09 = EBIT TTM 135.7m / Avg Total Assets 1.51b |
| (D) 2.62 = Book Value of Equity 1.72b / Total Liabilities 655.9m |
| Total Rating: 8.81 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 62.32
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 10.25% = 5.0 |
| 3. FCF Margin 3.60% = 0.90 |
| 4. Debt/Equity 0.32 = 2.45 |
| 5. Debt/Ebitda 1.27 = 1.36 |
| 6. ROIC - WACC 3.79% = 4.74 |
| 7. RoE 13.91% = 1.16 |
| 8. Rev. Trend -90.85% = -4.54 |
| 9. Rev. CAGR -11.35% = -1.89 |
| 10. EPS Trend 5.59% = 0.14 |
| 11. EPS CAGR 46.23% = 2.50 |
What is the price of NUS shares?
Over the past week, the price has changed by +0.84%, over one month by +41.40%, over three months by +46.66% and over the past year by +35.59%.
Is Nu Skin Enterprises a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NUS is around 10.95 USD . This means that NUS is currently overvalued and has a potential downside of -10.02%.
Is NUS a buy, sell or hold?
What are the forecasts/targets for the NUS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7.5 | -38.4% |
| Analysts Target Price | 7.5 | -38.4% |
| ValueRay Target Price | 12 | -1.8% |
Last update: 2025-08-21 02:49
NUS Fundamental Data Overview
CCE Cash And Equivalents = 264.2m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 5.8424
P/E Forward = 9.2593
P/S = 0.361
P/B = 0.7333
P/EG = 2.35
Beta = 0.888
Revenue TTM = 1.63b USD
EBIT TTM = 135.7m USD
EBITDA TTM = 196.7m USD
Long Term Debt = 213.9m USD (from longTermDebt, last quarter)
Short Term Debt = 35.0m USD (from shortTermDebt, last quarter)
Debt = 248.9m USD (Calculated: Short Term 35.0m + Long Term 213.9m)
Net Debt = 46.6m USD (from netDebt column, last quarter)
Enterprise Value = 571.8m USD (587.0m + Debt 248.9m - CCE 264.2m)
Interest Coverage Ratio = 7.47 (Ebit TTM 135.7m / Interest Expense TTM 18.2m)
FCF Yield = 10.25% (FCF TTM 58.6m / Enterprise Value 571.8m)
FCF Margin = 3.60% (FCF TTM 58.6m / Revenue TTM 1.63b)
Net Margin = 6.20% (Net Income TTM 100.8m / Revenue TTM 1.63b)
Gross Margin = 67.23% ((Revenue TTM 1.63b - Cost of Revenue TTM 533.0m) / Revenue TTM)
Tobins Q-Ratio = 0.33 (Enterprise Value 571.8m / Book Value Of Equity 1.72b)
Interest Expense / Debt = 1.01% (Interest Expense 2.53m / Debt 248.9m)
Taxrate = 22.95% (from quarterly Income Tax Expense: 6.29m / 27.4m)
NOPAT = 104.5m (EBIT 135.7m * (1 - 22.95%))
Current Ratio = 2.01 (Total Current Assets 571.6m / Total Current Liabilities 283.9m)
Debt / Equity = 0.32 (Debt 248.9m / last Quarter total Stockholder Equity 787.8m)
Debt / EBITDA = 1.27 (Net Debt 46.6m / EBITDA 196.7m)
Debt / FCF = 4.25 (Debt 248.9m / FCF TTM 58.6m)
Total Stockholder Equity = 725.0m (last 4 quarters mean)
RoA = 6.98% (Net Income 100.8m, Total Assets 1.44b )
RoE = 13.91% (Net Income TTM 100.8m / Total Stockholder Equity 725.0m)
RoCE = 14.45% (Ebit 135.7m / (Equity 725.0m + L.T.Debt 213.9m))
RoIC = 9.92% (NOPAT 104.5m / Invested Capital 1.05b)
WACC = 6.13% (E(587.0m)/V(835.9m) * Re(8.40%)) + (D(248.9m)/V(835.9m) * Rd(1.01%) * (1-Tc(0.23)))
Shares Correlation 5-Years: -70.0 | Cagr: -0.65%
Discount Rate = 8.40% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 76.72% ; FCFE base≈78.0m ; Y1≈76.5m ; Y5≈78.2m
Fair Price DCF = 26.26 (DCF Value 1.30b / Shares Outstanding 49.5m; 5y FCF grow -2.78% → 3.0% )
Revenue Correlation: -90.85 | Revenue CAGR: -11.35%
Rev Growth-of-Growth: -2.76
EPS Correlation: 5.59 | EPS CAGR: 46.23%
EPS Growth-of-Growth: 182.7
Additional Sources for NUS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle